RE:RE:RE:RE:Great 👍, , Waves cancer drug approved in Europe I agree and like the news out of Europe and the US. The cash bleed is an issue though, as it is with most promising companies of this size and I am interested to see what they do with Pemetrexed to bring in some revenue. The ANDA submission for the six generics in the US should not be that expensive to do, (even with consultants). The time to approval should be short as per the seriousness of the indications and drug cost sensitivities south of the border. I I have seen good things come out of Winnipeg and just initiated a position of what I hope is the long term. I noticed a drop in Admin Expenses in the last 2 quarters which is encouraging. The cash burn suggests a placement or non-dilutive financing in the near future. The company should look into consutants whose have successful experience in aqcuiring funding and grants for small BioTechs.